Cbay stock forecast.

Nov 29, 2023 · Future criteria checks 2/6. CymaBay Therapeutics is forecast to grow earnings and revenue by 47.6% and 61.6% per annum respectively. EPS is expected to grow by 45.7% per annum. Return on equity is forecast to be -57.1% in 3 years. Sep 19, 2023 · CymaBay Therapeutics, Inc. (CBAY) share price prediction for 2023, 2024, 2025, 2026 and 2027. CBAY one year forecast. Cymabay Therapeutics stock monthly and weekly ... Find the latest CymaBay Therapeutics, Inc. (CBAY) stock quote, history, news and other vital information to help you with your stock trading and investing. LifeSci Capital analyst Patrick Dolezal has maintained their bullish stance on CBAY stock, giving a Buy rating yesterday. Patrick Dolezal has given his Buy rating due to a combination of factors ...Based on short-term price targets offered by 11 analysts, the average price target for CymaBay Therapeutics Inc. comes to $24.45. The forecasts range from a low of $20.00 to a high of $34.00.

In today’s fast-paced business environment, accurate forecasting is crucial for making informed decisions and staying ahead of the competition. One powerful tool that can help you achieve this is a forecasting Excel template.

Based on analysts projections #CBAY is expected to experience a price decline over the next year. The current average CBAY price target, as estimated by these analysts, is $0.00.. The predictions for the future CBAY stock price range from a low of $0.00 to a high of $0.00, highlighting the variability of market expectations for CBAY.TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.com

Dec 1, 2023 · 7 brokers have issued 12-month price targets for Verastem's stock. Their VSTM share price targets range from $21.00 to $36.00. On average, they anticipate the company's share price to reach $29.71 in the next year. This suggests a possible upside of 362.1% from the stock's current price. View analysts price targets for VSTM or view top-rated ... Find the latest Absci Corporation (ABSI) stock quote, history, news and other vital information to help you with your stock trading and investing.Cymabay Therapeutics 's revenue in 2023 is $31,016,000. On average, 7 Wall Street analysts forecast CBAY's revenue for 2023 to be $3,523,442,178, with the lowest CBAY …September 8, 2023 at 1:12 PM · 3 min read. Shares of clinical-stage biopharmaceutical company CymaBay Therapeutics, Inc. CBAY gained after it announced positive top-line results from its late ...

Nov 29, 2023 · Predictions of CBAY stock price for tomorrow. 14-day Premium Trial Subscription Try For Free Get Free

The current CymaBay Therapeutics [ CBAY] share price is $17.90. The Score for CBAY is 74, which is 48% above its historic median score of 50, and infers lower risk than normal. CBAY is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.

The current CymaBay Therapeutics [ CBAY] share price is $17.90. The Score for CBAY is 74, which is 48% above its historic median score of 50, and infers lower risk than normal. CBAY is currently trading in the 70-80% percentile range relative to its historical Stock Score levels. Oct 15, 2020 · About the CymaBay Therapeutics, Inc. stock forecast. As of 2023 November 25, Saturday current price of CBAY stock is 19.100$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception). Find the latest Cidara Therapeutics, Inc. (CDTX) stock quote, history, news and other vital information to help you with your stock trading and investing.CymaBay Therapeutics Inc. (CBAY) stock forecast and price target. Find the latest CymaBay Therapeutics Inc. CBAY analyst stock forecast, price target, and recommendation trends with in-depth ... Based on analysts projections #CBAY is expected to experience a price decline over the next year. The current average CBAY price target, as estimated by these analysts, is $0.00.. The predictions for the future CBAY stock price range from a low of $0.00 to a high of $0.00, highlighting the variability of market expectations for CBAY.

Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Spruce Biosciences Inc have a median target of 8.50, with a high estimate of 10.00 and a low estimate of 7.00. The median ...Find real-time CPG - Crescent Point Energy Corp stock quotes, company profile, news and forecasts from CNN Business.AC Immune S.A. analyst ratings, historical stock prices, earnings estimates & actuals. ACIU updated stock price target summary.Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Spruce Biosciences Inc have a median target of 8.50, with a high estimate of 10.00 and a low estimate of 7.00. The median ...The above table shows the analyst CBAY forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$18.03

Find real-time ALDX - Aldeyra Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.

Future criteria checks 5/6. CymaBay Therapeutics is forecast to grow earnings and revenue by 59.3% and 61.1% per annum respectively. EPS is expected to …The Cymabay Therapeutics stock forecast is 22.75112265303 USD for 2024 November 25, Monday; and 52.714 USD for 2028 November 25, Saturday with technical analysis. Cymabay Therapeutics (CBAY) stock price prediction is 22.75112265303 USD.Nov 1, 2021 · For CymaBay Therapeutics stock forecast for 2023, 1 predictions are offered for each month of 2023 with average CymaBay Therapeutics stock forecast of $19.97, a high forecast of $19.97, and a low forecast of $19.97. The average CymaBay Therapeutics stock forecast 2023 represents a 4.58% increase from the last price of $19.1000003814697. Cymabay Therapeutics (CBAY) Company Description. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral ...Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Digital Turbine Inc have a median target of 5.50, with a high estimate of 12.00 and a low estimate of 5.00. The median ...Weather forecasts are essential tools for planning our daily activities, especially when it comes to the next 10 days. Understanding a weather 10 day forecast can help us make informed decisions about outdoor events, travel plans, or even w...

CBAY Stock Forecast: Positive Outlook and Analyst Consensus for CymaBay Therapeutics Inc. CBAY stock has been performing well in recent months, with positive forecasts from analysts. On June 30, 2023, the 10 analysts offering 12-month price forecasts for CBAY had a median target of $15.00, indicating a potential increase of …

Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...

(See CBAY stock forecast on TipRanks) AbSci Corporation . For the second penny stock we’ll look at, we’ll stick with the medical tech field – but look at a company with a different take on ...At the close of trading, the stock’s price was $2.30, to imply a decrease of -3.77% or -$0.09 in intraday trading. The ATUS share’s 52-week high remains $5.57, putting it -142.17% down since that peak but still an impressive 12.61% since price per share fell to its 52-week low of $2.01.Sep 8, 2023 · CymaBay (CBAY) Stock Up on Positive Results From PBC Study. ... The median home sale price will fall 1.7% next year after eking out an anticipated 0.2% gain in 2023, according to the forecast. TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comCymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the results from its RESPONSE Phase 3 registration study evaluating seladelpar, a potent, selective, orally-active delpar ...September 8, 2023 at 1:12 PM · 3 min read. Shares of clinical-stage biopharmaceutical company CymaBay Therapeutics, Inc. CBAY gained after it announced positive top-line results from its late ...In today’s fast-paced business environment, accurate forecasting is crucial for making informed decisions and staying ahead of the competition. One powerful tool that can help you achieve this is a forecasting Excel template.Shares of CymaBay Therapeutics ( CBAY -1.16%) were jumping 14.2% higher as of 10:54 a.m. ET on Friday. This move came on the heels of an 8.5% gain on Thursday. The continued momentum is a result ...Find real-time CELZ - Creative Medical Technology Holdings Inc stock quotes, company profile, news and forecasts from CNN Business.SPRB Stock 12 Months Forecast. $8.40. (510.91% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Spruce Biosciences in the last 3 months. The average price target is $8.40 with a high forecast of $10.00 and a low forecast of $7.00. The average price target represents a 510.91% change from the last price of $1.38.Nov 21, 2023 · According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecasts Nov 28, 2023 · Cymabay Therapeutics Inc (NASDAQ:CBAY) trade information. Instantly CBAY has been showing red trend so far today with a performance of -1.24% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently up 186.68% year-to-date, but still down -3.67% over the last five ...

Wall Street Stock Market & Finance report, prediction for the future: You'll find the CBAK Energy Technology share forecasts, stock quote and buy / sell signals below. According to present data CBAK Energy Technology's CBAT shares and potentially its market environment have been in bearish cycle last 12 months (if exists).Weather forecasts play an essential role in our daily lives, helping us plan our activities and stay prepared for any weather conditions that may come our way. One of the most common types of forecasts is the 7-day weather forecast, which p...Find the latest CymaBay Therapeutics, Inc. (CBAY) stock quote, history, news and other vital information to help you with your stock trading and investing.TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comInstagram:https://instagram. how to place a trade on forexsilver price predictions 2023ai character chat no filterfnbonlinebanking namibia Dec 1, 2023 · The consensus price target of analysts on Wall Street is $24.42, which implies an increase of 21.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $34.00 respectively. As a result, CBAY is trading at a discount of -77.73% off the target high and -4.55% off the low. 7 brokers have issued 12-month price targets for Verastem's stock. Their VSTM share price targets range from $21.00 to $36.00. On average, they anticipate the company's share price to reach $29.71 in the next year. This suggests a possible upside of 362.1% from the stock's current price. View analysts price targets for VSTM or view top … how to invest in brics currencymagnifi ai reviews CDTX Stock 12 Months Forecast. Based on 1 Wall Street analysts offering 12 month price targets for Cidara Therapeutics in the last 3 months. The average price target is $6.00 with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 679.22% change from the last price of $0.77.Stock Price Forecast The 8 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 11.00, with a high estimate of. ... What is The target price for CBAY? The 8 analysts offering 12-month price forecasts for Cymabay Therapeutics Inc have a median target of 11.00, with a high estimate of 14.00 and a low … best fractional ownership properties Nov 13. 4.17%. $94.57. Check if AHPI Stock has a Buy or Sell Evaluation. AHPI Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Allied Healthcare Products News.Based on 10 Wall Street analysts offering 12 month price targets for CymaBay Therapeutics in the last 3 months. The average price target is $24.40 with a high forecast of $33.00 and a low forecast of $20.00. The average price target represents a 29.93% change from the last price of $18.78. Highest Price Target $33.00. Average Price Target $24.40.Their PTGX share price targets range from $32.00 to $38.00. On average, they expect the company's share price to reach $35.25 in the next twelve months. This suggests a possible upside of 109.4% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts.